A Comprehensive Review of MDMA and GHB: Two Common Club Drugs
Christian J. Teter, Sally K. Guthrie
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy December 1, 2001 DOI: 10.1592/phco.21.20.1486.34472 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | MDMA Serotonin |
| Keywords | Rhabdomyolysis Gamma hydroxybutyrate Serotonin syndrome Coma optics Anesthesia Intensive care medicine Euphoriant Amphetamine Narcolepsy Hallucinogen Modafinil Pharmacology Dopamine |
| Citations | 114 |
| Key findings | MDMA and GHB have nonlinear pharmacokinetics, produce distinct toxic syndromes, and require specific supportive treatments. |
Abstract
“Club drugs” have become alarmingly popular. The use of 3,4‐methylenedioxymethamphetamine (MDMA, Ecstasy) and γ‐hydroxybutyrate (GHB), in particular, has increased dramatically from 1997–1999. The pharmacokinetics of MDMA and GHB appear to be nonlinear, making it difficult to estimate a dose‐response relationship. The drug MDMA is an amphetamine analog with sympathomimetic properties, whereas GHB is a γ‐aminobutyric acid analog with sedative properties. Symptoms of an MDMA toxic reaction include tachycardia, sweating, and hyperthermia. Occasional severe sequelae include disseminated intravascular coagulation, rhabdomyolysis, and acute renal failure. Treatment includes lowering the body temperature and maintaining adequate hydration. Symptoms of GHB intoxication include coma, respiratory depression, unusual movements, confusion, amnesia, and vomiting. Treatment includes cardiac and respiratory support. Because of the popularity of these agents and their potentially dangerous effects, health care professionals must be familiar with these substances and the treatment options for patients who present with symptoms of a toxic reaction.
Comparable studies
Other narrative reviews on MDMA, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Human Pharmacology of MDMA | 2004 | Review | |
| Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research | 2001 | Review | |
| 3,4‐Methylenedioxymethamphetamine (MDMA, “Ecstasy”): pharmacology and toxicology in animals and humans | 1994 | Review | |
| (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Studies in Animals | 2000 | Review | |
| Amphetamine toxicities | 2010 | Review |
Citations in the library
Cited by 7
- Importance of ERK activation in behavioral and biochemical effects induced by MDMA in mice British Journal of Pharmacology October 29, 2003
- Long-Term Neuropsychiatric Consequences of "Ecstasy" (MDMA): A Review Harvard Review of Psychiatry 2002
- Pharmacological aspects of the combined use of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and gamma-hydroxybutyric acid (GHB): a review of the literature Drug and Alcohol Review July 1, 2005
- Assessment of the Reinforcing Properties of Orally Administered MDMA ('Ecstasy') in Rats 2010
- Death from a possible anaphylactic reaction to ecstasy. Clinical Toxicology February 2008
and 2 more in the library
Cites 67
- Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings The Lancet October 1, 1998
- Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens Journal of Psychoactive Drugs October 1, 1986
- Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity Journal of Neuroscience August 1, 1988
- 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. Journal of Pharmacology and Experimental Therapeutics September 1, 1987
- Subjective Reports of the Effects of MDMA in a Clinical Setting Journal of Psychoactive Drugs October 1, 1986
and 62 more in the library